CIK 0002058707 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Attovia Therapeutics, Inc.
Sign in to watch- Ticker
- ATTO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 921510574
- Phone
- 5103995001
- Business address
- 1091 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-06 | Deep Track Biotechnology Master Fund, Ltd. 10% owner | Conversion | +1,957,138 | 1,957,138 | ||
| 2026-08-06 | Deep Track Biotechnology Master Fund, Ltd. 10% owner | Conversion · Series C Redeemable Convertible Preferred Stock | −18,181,818 | |||
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. 10% owner | Conversion | +2,311,870 | 2,311,870 | ||
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. 10% owner | Conversion | +821,998 | 3,133,868 | ||
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. 10% owner | Conversion | +665,147 | 3,799,015 | ||
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. 10% owner | Purchase | +382,352 | $17.00 | $6.5M | 4,181,367 |
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. 10% owner | Conversion · Series A Preferred Stock | −21,477,273 | 0 | ||
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. 10% owner | Conversion · Series B Preferred Stock | −7,636,362 | 0 | ||
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. 10% owner | Conversion · Series C Preferred Stock | −6,179,219 | 0 | ||
| 2026-08-06 | Sanofi 10% owner | Conversion | +782,855 | 782,855 | ||
| 2026-08-06 | Sanofi 10% owner | Purchase | +300,000 | $17.00 | $5.1M | 1,082,855 |
| 2026-08-06 | Sanofi 10% owner | Conversion · Series C Preferred Stock | −782,855 | 0 | ||
| 2026-08-06 | Redmile Group, LLC 10% owner | Conversion | +782,854 | 782,854 | ||
| 2026-08-06 | Redmile Group, LLC 10% owner | Purchase | +200,000 | $17.00 | $3.4M | 982,854 |
| 2026-08-06 | Redmile Group, LLC 10% owner | Purchase | +400,000 | $17.00 | $6.8M | 1,182,854 |
| 2026-08-06 | Redmile Group, LLC 10% owner | Conversion · Series B Preferred Stock | −782,854 | 0 | ||
| 2026-08-06 | Frazier Life Sciences XI, L.P. 10% owner | Conversion | +1,749,192 | 1,824,541 | ||
| 2026-08-06 | Frazier Life Sciences XI, L.P. 10% owner | Conversion | +1,590,175 | 3,414,716 | ||
| 2026-08-06 | Frazier Life Sciences XI, L.P. 10% owner | Conversion | +1,189,940 | 4,604,656 | ||
| 2026-08-06 | Frazier Life Sciences XI, L.P. 10% owner | Conversion | +961,322 | 5,565,978 |
Page 2 of 9 · 162 trades